Business Wire

Pantheon expands international private wealth offerings with evergreen private credit secondary fund

15.4.2025 10:21:00 CEST | Business Wire | Press Release

Share

Pantheon, a leading global private markets investor, today announced that it has successfully launched the Pantheon Global Credit Secondaries Fund (PGCS)1, the latest, and seventh, addition to the firm’s growing private wealth platform. PGCS is an evergreen, semi-liquid fund which will be anchored in private credit secondaries — providing international investors with access to transactions completed by Pantheon’s global private credit platform through a single investment. PGCS will have a quarterly liquidity mechanism and will soon be available in 20+ countries across EMEA, Latin America, APAC, and Australia.

PGCS aims to offer investors attractive absolute and risk-adjusted returns by building a diversified portfolio of seasoned, funded, and performing private credit, primarily acquired via LP interests and GP liquidity solutions. The Fund will invest in direct lending strategies and opportunistic credit strategies, aiming to deliver a compelling combination of yield and compounding. Leveraging over three decades of expertise in evergreen product structuring, Pantheon is focused on meeting the complex needs of private wealth investors seeking diversified portfolios and access to exclusive market segments.

Pantheon’s diverse global private wealth platform

The fund launch builds on the momentum and success of Pantheon’s $10.6bn2 global private wealth platform, which has a 38-year track record of providing individual investors access to private markets investing. Pantheon is differentiated within the industry by the breadth of its evergreen fund solutions, which offer investors access to key asset classes through a range of US, UK and International evergreen fund solutions3. This includes the AMG Pantheon Fund (P-PEXX), one of the largest and most established registered private equity funds in the US with approximately $4.7bn4 in assets under management, and the newly-launched private credit secondaries-focused evergreen fund, the AMG Pantheon Credit Solutions Fund (P-SECC). Along with the two established US vehicles, and Pantheon’s broader International Private Wealth platform — which includes the Pantheon Global Private Equity (PGPE) Fund — Pantheon also manages two UK-listed investment trusts, Pantheon International Plc (PIP) and Pantheon Infrastructure Plc (PINT).

Pantheon’s expertise in private credit secondaries strategies

Pantheon has been at the forefront of private credit secondaries since launching the market’s first dedicated fund in 2018. Since that time, the firm has committed approximately $7.9 billion5 to private credit secondaries transactions and has raised over $10.1 billion6 from a range of institutional and private wealth investors7. Most recently, Pantheon’s third senior credit secondaries program (PSD III) closed at $5.2bn, consisting of closed-end co-mingled funds, evergreen and rated insurance vehicles, and separately managed accounts.

Currently, Pantheon’s investment vehicles provide exposure to more than 90 private credit GPs and approximately 5,400 companies worldwide6. Pantheon’s dedicated private credit team has a proven track record of sourcing and managing high-quality secondary investments, providing strong risk management and generating attractive performance8. The firm’s comprehensive private credit strategies invest across the entire credit spectrum, providing clients with diversified access to the asset class and a range of investment solutions.

Rakesh (Rick) Jain, Portfolio Manager and Global Head of Private Credit, commented, “We are proud to be a leading provider of private credit secondaries solutions offerings to our clients globally. We bring significant scale in both capital and transaction experience and a strong partnership approach with both LPs and GPs.”

Toni Vainio, Portfolio Manager and Head of European Private Credit, commented, “We are pleased to provide an attractive access point for diversified global credit secondaries, a growing and attractive sub-segment of the secondaries market, to investors in the international wealth channel.”

Victor Mayer, Head of International Private Wealth said, “Building on PGPE's international success, we're excited to extend Pantheon's specialized semi-liquid expertise into private credit secondaries. Allowing our investors to seek compelling returns and income amid rate fluctuations and persistent inflation — providing international clients with access to the fast-growing credit secondaries market at an enticing time of development.”

About Pantheon

Pantheon* has been at the forefront of private markets investing for more than 40 years, earning a reputation for providing innovative solutions covering the full lifecycle of investments, from primary fund commitments to co-investments and secondary purchases, across private equity, private credit, infrastructure, and real assets.

We have partnered with more than 650 clients, including institutional investors of all sizes as well as a growing number of private wealth advisers and investors, with approximately $70.8bn in discretionary assets under management (as of September 30, 2024).

Leveraging our specialized experience and global team of professionals across Europe, the Americas and Asia, we invest with purpose and lead with expertise to build secure financial futures.

* Pantheon refers to the subsidiaries and subsidiary undertakings of Pantheon Ventures Inc. and AMG Plymouth UK Holdings Limited and includes operating entities principally based in the US (San Francisco and New York), UK (London), Hong Kong, Guernsey, Tokyo, Dublin and Singapore. Pantheon Ventures Inc. and Pantheon Ventures (US) LP are registered as investment advisors with the U.S. Securities and Exchange Commission (“SEC”); Pantheon Securities, LLC is a broker dealer registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”). Pantheon Ventures (UK) LLP is authorized and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom. Pantheon Ventures (Guernsey) Ltd and a number of other Pantheon entities incorporated in Guernsey are regulated by the Guernsey Financial Services Commission. Pantheon Ventures (Asia) Limited is registered as a Type II Financial Instruments Business and Investment Advisory and Agency Business Operator with the Kanto Local Finance Bureau in Japan (KLFB). Pantheon Ventures (Ireland) DAC is regulated by the Central Bank of Ireland (“CBI”) and is an appointed representative of Pantheon Ventures (UK) LLP in respect of activities carried out in the United Kingdom. Pantheon Ventures (Singapore) Pte. Ltd holds a capital markets service license from the Monetary Authority of Singapore (“MAS”) to conduct fund management with accredited and institutional investors.

This press release is not an offer of securities for sale. Securities may not be offered or sold in the United States absent registration or an exemption from registration. © 2025

1 For Professional or Qualified Investors only, as applicable. This is a marketing communication, please refer to the Prospectus before making a final investment decision.
2 The NAVs of all underlying private wealth vehicles are as at September 30, 2024, and expressed in US$ terms. Source Pantheon.
3 Pantheon opinion.
4 As of December 31, 2024.
5 Includes all capital committed to credit secondaries investments by Pantheon Private Credit clients from the inception of the private credit program in 2018 through to March 31, 2025.
6 Includes all private credit capital raised for commingled funds, SMAs and evergreen strategies from the formalization of the private credit program through to April 8, 2025.
7 As of January 2025, inclusive of all credit secondaries and co-investments closed from credit secondary-focused commingled funds, SMAs and evergreen vehicles since 2018. In addition, Pantheon has committed $543m to 27 primaries.
8 Pantheon opinion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250414258316/en/

Contacts

Notes to Editors
For further information, please contact:
Pantheon
Mariella Reason, Pantheon Communications
Tel: +44 20 3473 3975 | Email: mariella.reason@pantheon.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye